Alantra advises Guardion Health on strategic sale of Viactiv to KingdomWay Group
SECTORHealthcare
ServiceM&A
New York – Alantra has advised Guardion Health Sciences, Inc. (NASDAQ: GHSI) in the successful sale of its primary branded OTC asset, Viactiv, to KingdomWay Group (SZSE: 002626), a prominent Chinese company specializing in nutrition enhancers and biomedical products. KingdomWay has acquired 100% of the public shares of Viactiv as part of this strategic transaction.
Viactiv, a well-established OTC brand known for its health supplements, particularly in the area of bone health, fits well within KingdomWay’s growing portfolio of nutritional and biomedical products. The acquisition aligns with KingdomWay’s strategic objectives to expand its presence in the global health and wellness market.
Guardion Health Sciences, based in San Diego, California, operates as a specialty health sciences company with two primary segments: Medical Foods and Nutraceuticals, and Medical Devices. Its product portfolio includes Lumega-Z, GlaucoCetin, MapcatSF, CSV-1000, CSV-2000, and various nutraceuticals under the NutriGuard brand. This sale of Viactiv allows Guardion to focus more intensively on its core operations in medical foods and devices.
KingdomWay, headquartered in Xiamen, China, is recognized globally for its production of nutrition enhancers and biomedical products, including Coenzyme Q10, microalgae DHA, vegetable ARA, Vitamin A, and Vitamin D3. The acquisition of Viactiv marks a significant step in KingdomWay’s expansion into the international OTC market.
This transaction underscores Alantra’s deep expertise in the healthcare and consumer sectors, particularly in the complex OTC market. With prior experience handling Viactiv’s sale, Alantra’s familiarity with the brand’s intricate supply chain enabled the team to navigate the complexities of the transaction smoothly. This successful deal exemplifies Alantra’s strong track record in advising clients on strategic transactions that create value and align with long-term business goals.
Related Transactions
-
Oct 2024Sell-side advisoryOct 2024SECTOR HealthcareService M&A
-
Oct 2024Sell-side advisoryOct 2024SECTOR Consumer Goods & Retail; HealthcareService M&A
-
Oct 2024Sell-side advisoryOct 2024SECTOR Consumer Goods & Retail; HealthcareService M&A
-
Aug 2024Sell-side AdvisoryAug 2024SECTOR HealthcareService M&A